Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor + RCHOP in Double/Triple Hit Lymphoma
NCT05974085Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Aug 2022
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of selinexor in high-grade B-cell lymphoma with double-hit genetics (DHL), triple-hit lymphoma (THL), sponsored by Zhejiang Cancer Hospital. Status: unknown.
02
Drugs
selinexor
03
Conditions
high-grade B-cell lymphoma with double-hit genetics (DHL)triple-hit lymphoma (THL)
Beyond the preview
Go deeper on NCT05974085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05974085.